Jefferies is out with its report today on Amarin AMRN, maintaining Buy.
In a note to clients, Jefferies writes, "A competitor has raised questions raised over the validity of the statistical
analyses used in the MARINE and ANCHOR studies, but for reasons we outline below, we remain positive on the statistical analysis plans and the eventual AMR101 commercial label. We continue to believe in a multi-billion market opportunity for AMR101. AMRN remains one of our top biotech picks."
Jefferies maintains a $25 PT on AMRN.
At the time of posting, shares of AMRN were trading pre-market at $18.86, up 1.84% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in